Phase II Study Results Show Up to 93% Reduction in New Gadolinium-Enhancing Lesions
CLINICAL STUDY RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SHOW PROMISING DATA ON ANTEGREN-® (natalizumab) IN THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS
169.7K
0